Adoption of Dupixent Across Multiple Indications Drives U.S. Market Performance

July 18, 2025

The U.S. Dupixent market, valued at USD 11.04 billion in 2024, is projected to grow at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2034, reflecting its entrenched position in the biologics landscape for chronic inflammatory diseases. Dupixent (dupilumab), developed by Regeneron Pharmaceuticals and co-commercialized with Sanofi, has become a cornerstone therapy for moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. While the U.S. remains the largest revenue contributor, regional manufacturing trends and cross-border supply chain dynamics are increasingly shaping the drug’s global trajectory. The U.S. benefits from a well-established biologics manufacturing infrastructure, which supports rapid scale-up of production and efficient distribution, reinforcing its leadership in the global Dupixent ecosystem.

In Europe, regulatory support and national reimbursement frameworks are fueling strong adoption, particularly in Germany, France, and the U.K. The European Medicines Agency (EMA) has approved Dupixent across multiple indications, and health technology assessment bodies have generally recognized its cost-effectiveness in treating atopic conditions. However, regional disparities in market penetration strategies persist, with Southern and Eastern European countries lagging due to budgetary constraints and slower regulatory approvals. The region’s biopharma industry is also undergoing a shift toward localized manufacturing and nearshoring, partly in response to post-pandemic supply chain disruptions and geopolitical uncertainty. This trend is influencing cross-border supply chains and prompting manufacturers to re-evaluate their production footprints to ensure continuity of supply.

Asia Pacific presents a more complex landscape, with Japan and South Korea leading in early adoption due to mature healthcare systems and favorable regulatory pathways. Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has expedited the approval of Dupixent for atopic dermatitis and asthma, enabling faster market entry compared to other emerging markets. In contrast, China and India are experiencing slower uptake due to high out-of-pocket costs, limited insurance coverage, and the presence of biosimilar competition. However, as China continues to modernize its regulatory framework and expand its biologics manufacturing capabilities, it is expected to become a key growth driver in the coming decade. Regional manufacturing trends in China are increasingly aligned with global standards, with domestic contract manufacturing organizations (CMOs) partnering with multinational firms to produce biosimilars and support supply chain localization.

Market dynamics are further influenced by trade-specific factors, particularly in the context of U.S.-China trade tensions and the global push for supply chain resilience. The U.S. has seen a renewed emphasis on domestic API (active pharmaceutical ingredient) production, reducing reliance on offshore suppliers and mitigating risks associated with geopolitical instability. This shift has implications for Dupixent’s long-term supply strategy, as both Regeneron and Sanofi are investing in U.S.-based manufacturing facilities to secure production and maintain quality control. These developments are reshaping regional manufacturing trends and reinforcing the U.S.’s strategic advantage in the global biologics space.

Market Drivers include rising prevalence of allergic and inflammatory diseases, strong clinical efficacy data, and increasing patient access through expanded indications. Restraints include high treatment costs, limited reimbursement in emerging markets, and the threat of biosimilar competition. Opportunities lie in label expansions into new indications such as eosinophilic esophagitis and prurigo nodularis, as well as strategic partnerships to improve market penetration in Asia and Latin America. Trends shaping the market include the rise of precision medicine, the integration of digital health tools for patient monitoring, and the growing importance of cross-border supply chain resilience in biologics manufacturing.

As the U.S. Dupixent market continues to evolve, success will depend on a company’s ability to align with regional manufacturing trends, navigate cross-border supply chain complexities, and implement effective market penetration strategies across diverse geographies.